Opinion|Videos|December 28, 2023

NSCLC: Role of ADCs and Ongoing EVOKE-01 and EVOKE-03 Studies

Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS

Medical oncologists discuss where antibody-drug conjugates fit in the overall non–small cell lung cancer treatment landscape and review the ongoing EVOKE-01 and EVOKE-03 clinical trials.

Episodes in this series

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 1 Overview of Non–Small Cell Lung Cancer

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 2 The Role of Biomarkers in NSCLC Treatment

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 3 NSCLC Treatment: Unmet Needs and Antibody-Drug Conjugates

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 4 The Role of TROP2 as a Biomarker in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 5 NSCLC: Preclinical Studies on TROP2 Expression

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 6 Lung Cancer Treatment: Antibody-Drug Conjugates

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 7 Clinical Trial Data on Sacituzumab Govitecan in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 8 EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 9 Advanced NSCLC: TROPION-Lung02 and TROPION-Lung04

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 10 Antibody-Drug Conjugate Safety Profiles in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 11 Recent Data on Datopotamab Deruxtecan in NSCLC

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 12 NSCLC: Dato-DXd Combination Therapy

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 13 NSCLC: Role of ADCs and Ongoing EVOKE-01 and EVOKE-03 Studies

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 14 Progress and Unmet Needs in NSCLC Treatment

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer

EP. 15 Future Targeted Therapy Approaches in NSCLC

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Firmonertinib Misses PFS End Point in EGFR Exon 20–Mutant NSCLC

October 6th, 2026

Firmonertinib Misses PFS End Point in EGFR Exon 20–Mutant NSCLC

Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR Exon 20–Mutant NSCLC.

NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC

October 2nd, 2026

NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC

Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.

Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC

September 30th, 2026

Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC

FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.

Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer

September 29th, 2026

Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Aglatimagene Boosts Immune Infiltration in Localized Prostate Cancer

Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer

Epcoritamab Plus R-CHOP Improves PFS in Newly Diagnosed DLBCL

Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC

Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer